• Raised $3.2M via a two-tranche placement at $0.12 per share
• Funds to accelerate sales and marketing efforts in the US and beyond
• Company has three established product ranges generating revenue, with a fourth product line launching soon

ReNerve Limited (ASX: RNV) has received commitments from new and existing institutional and sophisticated investors to raise approximately $3.2M before costs via a two-tranche placement. The placement will see the company issue approximately 26,666,667 fully paid ordinary shares at $0.12 per share, representing a 22.6% discount to the last closing price and a 28.2% discount to the 15-day VWAP. Tranche 1 of the placement, raising $2.6M, will be issued under the company's existing placement capacity, while Tranche 2, raising $0.6M, is subject to shareholder approval. The funds raised will enable ReNerve to accelerate its sales and marketing programs for its existing product lines, including the NervAlign® Nerve Cuff and EmpliQ ranges, as well as support the ongoing development of new products such as its nerve conduit and nerve guide matrix offerings. The company also plans to strengthen its sales team. ReNerve is transforming nerve repair with its innovative, ready-to-use solutions for peripheral nerve injuries, and has demonstrated strong market traction since its 2022 product launch, achieving 53% revenue growth in FY25 to reach $271k in sales. The company is positioning itself as a leader in the rapidly expanding global nerve repair market, valued at $1.6 billion in 2024 and projected to reach $6.2 billion by 2031.

2026 is shaping up to be a transformational year for ReNerve, with several pivotal milestones on the horizon that the company believes will be material to shareholders.